1. 153OM7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype. (25th November 2018) Authors: Yoo, C; Oh, D-Y; Choi, H J; Kudo, M; Ueno, M; Kondo, S; Chen, L-T; Osada, M; Helwig, C; Dussault, I; Ikeda, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 156PTCOG T1308 study: The final results of a phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer. (25th November 2018) Authors: Chiang, N-J; Chen, L-T; Chen, J-S; Yang, S-H; Hsu, C; Shan, Y-S; Yen, C-J; Chen, M-H; Tsou, H-H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 200PLiposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study. (25th November 2018) Authors: Chen, L-T; Macarulla Mercadé, T; Lee, K-H; Lakatos, G; Wang-Gillam, A; Mirakhur, B; de Jong, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 617PDA phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data. (23rd October 2018) Authors: Satoh, T; Chen, L-T; Kang, Y-K; Chao, Y; Kato, K; Chung, H C; Chen, J-S; Muro, K; Kang, W K; Yoshikawa, T; Oh, S C; Tamura, T; Lee, K-W; Boku, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 626PDRandomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study. (23rd October 2018) Authors: Chang, H-J; Chiu, Y-F; Chen, J-S; Li, C-P; Ho, C-L; Shyr, Y-M; Chiou, W-C; Yeh, C-N; Hsieh, R-K; Lin, Y-L; Tien, Y-W; Hwang, T-L; Shan, Y-S; Chen, L-T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 733PNAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). (23rd October 2018) Authors: Macarulla Mercade, T; Bodoky, G; Siveke, J; Lee, K-H; Chen, J; Mirakhur, B; Dean, A; Chen, L-T; de Jong, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 734PImpact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1. (23rd October 2018) Authors: Chen, L-T; Macarulla, T M; Blanc, J; Mirakhur, B; de Jong, F A; Belanger, B; Bekaii-Saab, T; Siveke, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 736PMulticenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study. (23rd October 2018) Authors: Chiang, N-J; Tsai, K K; Chen, J-S; Yang, S-H; Hsiao, H-H; Shan, Y-S; Chen, L-T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 749PThe prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV). (23rd October 2018) Authors: Chen, L-T; Macarulla, T M; Belanger, B; Mirakhur, B; de Jong, F A; Siveke, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 757PM7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial. (23rd October 2018) Authors: Yoo, C; Oh, D-Y; Choi, H J; Kudo, M; Ueno, M; Kondo, S; Chen, L-T; Osada, M; Helwig, C; Dussault, I; Ikeda, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗